Talk:Mebroqualone

Fatal overdose may occur when GABAergic substances are combined with other depressants such as opiates, benzodiazepines, barbiturates, gabapentinoids, thienodiazepines or alcohol.

It is strongly discouraged to combine these substances, particularly in common to heavy doses.

Summary sheet: Mebroqualone

Mebroqualone
Chemical Nomenclature
Common names	Mebroqualone
Substitutive name	Mebroqualone
Systematic name	3-(2-bromophenyl)-2-methylquinazolin-4(3H)-one
Class Membership
Psychoactive class	Depressant
Chemical class	Quinazolinone
Routes of Administration
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section. ⇣ Smoked Dosage Threshold 2 mg Light 2 - 4 mg Common 4 - 8 mg Strong 8 - 12 mg Heavy 12mg + Duration Total 1 - 2 hours Onset 10 - 20 seconds ⇣ Oral Dosage Threshold 3 mg Light 3 - 5 mg Common 5 - 10 mg Strong 10 - 15 mg Heavy 15 mg + Duration Total 1 - 2 hours Onset 20 - 30 minutes DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
Interactions

Mebroqualone is a central nervous system (CNS) depressant of the quinazolinone class that acts as a sedative and hypnotic.

Not much is known about this substance besides it being significantly more potent than methaqualone and shorter-lasting. It should be noted that methaqualone and its derivatives are prone to dangerous side effects such as respiratory depression and convulsions. It is therefore highly suggested to use harm reduction practices if using this substance.

Chemistry

Mebroqualone, or 2-methyl-3-(2-methylphenyl)-4(3H)-quinazolinone, is a compound of the quinazolinone class. Quinazolinone is a bicyclic structure containing a phenyl ring bound to another six-membered ring with two nitrogen members and a ketone group bound to R₄. In Mebroqualone, this structure is substituted at R₂ with a methyl group. Additionally, Mebroqualone contains a phenyl ring with a methyl group bound to R₂ which is attached to the quinazolinone structure at R₃.

Pharmacology

This pharmacology section is incomplete. You can help by adding to it.

Despite prior speculation, a 2015 study demonstrates that Mebroqualone exhibits distinct functional properties at the GABA receptor sites compared with other allosteric modulators, and it mediates these through a different mechanism than the barbiturates and benzodiazepines that it historically has been lumped together with.

These distinctions could contribute to the reported differences in the in vivo effects induced by Mebroqualone and classic CNS depressants. In any case, the multifaceted functionality of Mebroqualone at GABA A receptors seems to be at the root of its clinical efficacy, as well as the addiction liability and recreational use associated with the drug.

It could be speculated that despite differences in targeted receptors, Mebroqualone essentially produces a variety of effects by binding to its receptor sites and magnifying the efficiency and effects of the neurotransmitter gamma aminobutyric acid (GABA) by acting on its receptors. As this site is the most prolific inhibitory receptor set within the brain, its modulation would explain the resulting sedating or calming effects which ensue.

Subjective effects

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

• • Sedation - In terms of energy level alterations, this drug is extremely sedating and often results in an overwhelmingly lethargic state. At higher levels, this causes users to suddenly feel as if they are extremely sleep deprived and have not slept for days, forcing them to sit down and generally feel as if they are constantly on the verge of passing out instead of engaging in physical activities. This sense of sleep deprivation increases proportional to dosage and eventually becomes powerful enough to force a person into complete unconsciousness.
  • Physical euphoria - This compound is unusually euphoric in comparison to other compounds within the same class.
  • Dizziness
  • Muscle relaxation
  • Motor control loss
  • Respiratory depression
  • Constipation
  • Changes in felt gravity
  • Seizures - Methaqualone and its analogs are known to cause convulsions, this might also be the case for mebroqualone.

Visual effects

• The visual effects of Mebroqualone are unusually strong for other depressants of its class. They can be broken down into several components which progressively intensify proportional to dosage.
  • Visual acuity suppression
  • Double vision
  • Visual disconnection - A sense of subtle disconnection from visual input is often experienced with high dosage Mebroqualone.
  • Internal hallucination - The internal hallucinations of Mebroqualone can be described as more solid than psychedelics and do not seem to be composed of visual geometry. The most common way in which they manifest themselves are through hypnagogic scenarios. They are most common during high dosages and can be comprehensively described through their variations as lucid in believability, fixed in style, autonomous in controllability, and equal in new experiences and memory replays in content.

Cognitive effects

• • Anxiety suppression
  • Thought deceleration
  • Disinhibition
  • Autonomous voice communication
  • Dream potentiation
  • Analysis suppression
  • Euphoria
  • Compulsive redosing
  • Increased libido
  • Increased music appreciation

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index.

Toxicity and harm potential

Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

Although the exact lethal dosage of Mebroqualone has not been formally established, like many depressants, it is safe at appropriate dosages. Complications may arise when administered in excess or in combination with other depressants.

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

Mebroqualone is extremely addictive. Tolerance to the sedative-hypnotic effects develops within a couple of days of repeated administration. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). Mebroqualone presents cross-tolerance with all gabaergic depressants, meaning that after the consumption of Mebroqualone all compounds of the same class will have a reduced effect.

Abrupt discontinuation of Mebroqualone following regular dosing over several days can result in a withdrawal phase which includes rebound symptoms such as increased anxiety and insomnia. It is possible to gradually reduce the dose over the course of several days, which will lengthen the duration of the withdrawal period but reduce the perceived intensity.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

• Depressants (1,4-Butanediol, 2M2B, alcohol, benzodiazepines, barbiturates, GHB/GBL, methaqualone, opioids) - This combination potentiates the muscle relaxation, amnesia, sedation, and respiratory depression caused by one another. At higher doses, it can lead to a sudden, unexpected loss of consciousness along with a dangerous amount of depressed respiration. There is also an increased risk of suffocating on one's vomit while unconscious. If nausea or vomiting occurs before a loss of consciousness, users should attempt to fall asleep in the recovery position or have a friend move them into it.
• Dissociatives - This combination can unpredictably potentiate the amnesia, sedation, motor control loss and delusions that can be caused by each other. It may also result in a sudden loss of consciousness accompanied by a dangerous degree of respiratory depression. If nausea or vomiting occurs before consciousness is lost, users should attempt to fall asleep in the recovery position or have a friend move them into it.
• Stimulants - Stimulants mask the sedative effect of depressants, which is the main factor most people use to gauge their level of intoxication. Once the stimulant effects wear off, the effects of the depressant will significantly increase, leading to intensified disinhibition, motor control loss, and dangerous black-out states. This combination can also potentially result in severe dehydration if one's fluid intake is not closely monitored. If choosing to combine these substances, one should strictly limit themselves to a pre-set schedule of dosing only a certain amount per hour until a maximum threshold has been reached.

Legal status

• Australia - Mebroqualone is Schedule 9 in Australia, meaning it is illegal without a license and deemed to have no medical value.
• Austria - Mebroqualone is illegal to possess, produce and sell under the SMG (Suchtmittelgesetz Österreich).
• Canada - Mebroqualone is Schedule III in Canada, meaning it requires a prescription or license to legally possess.
• Germany - Mebroqualone is Schedule III in Germany.
• United Kingdom - Mebroqualone is a Class B drug.
• United States - Mebroqualone is unscheduled in the United States. It may be considered an analogue of Mecloqualone, a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.

See also

• Responsible use
• Depressants
• Methaqualone
• GHB

External links

• Mebroqualone (Wikipedia)
• Mebroqualone (Isomer Design)
• Quaaludes (Drugs.com)